A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion
Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member
PUBLICATIONS
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.COMMENTARY
Do Biologics Protect Against COVID-19 Infection?
In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments. This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls. The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts. To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers. These findings led the authors to conclude that patients with IMIDs on cytokine inhibitor therapies have reduced susceptibility to SARS-CoV2 infection compared with patients not receiving cytokine-inhibitors, as well as the general population.
While these findings are highly intriguing, they have to be taken with caution. Thus, while the findings described here are significant, they are based on very small sample sizes and lack validation from an independent cohort. Furthermore, using a survey to control for exposure is likely inadequate as it may not capture subtle changes in behavior that are not easily caught on survey questionnaires. In addition, while these treatments inhibit specific inflammatory pathways and may be protective against more severe COVID-192, it is hard to envision how they’d prevent seroconversion of exposed patients. This is supported by studies showing blunted, but not absent, vaccination responses to influenza vaccine3. Lastly, if the implications of this study hold true, it would also have potential implications regarding the utility of vaccinating patients for COVID while on biologics.
In summary, while these findings are intriguing, the message from this paper that patients with IMIDs on biologics are protected against COVID-19 infection has to be taken with great caution. More extensive and robust studies are required before we can confidently determine that biologics protect against SARS-CoV-2 infection.
Reference:
Categories
Recent Posts
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD
Also Read
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
Subscribe to the IPC Newsletter